Press Enter to search · ESC to close

US Stocks

FDA Issues Complete Response Letter for Summit’s Ivonescimab BLA

Summit Therapeutics said the U.S. Food and Drug Administration issued a Complete Response Letter for its Biologics License Application for ivonescimab combined with platinum-based chemotherapy in previously treated EGFR TKI-treated locally advanced or metastatic non-small cell lung cancer. The FDA action blocks the drug’s U.S. approval for that indication, with overall survival not yet established as a key endpoint.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback